Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 9 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD).
NCT03481569 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 176
Last updated 2023-07-10
Summary
Nosocomial Central Nervous System infections are difficult to treat and an early appropriate therapy can improve prognosis. The two main reasons for treatments failure are the difficulty to reach high concentrations of antibiotics (ATB) in CNS because of brain barriers (BB), and the emergence of Multi-Drug-Resistant (MDR) pathogens that require high ATB concentrations for being killed. Therefore a better knowledge of ATB CNS distribution and PK-PD characteristics is essential for efficiency of treatments and to avoid resistance progression. Because of BB and cerebrospinal fluid (CSF) turnover, unbound (active) concentrations of ATB in CSF are frequently much lower than corresponding plasma concentrations, which therefore may not be used to predict efficacy. However except for patients with EVD, CSF access is difficult. Overall the litterature about ATB distribution within CSF exist but PK-PD publications are rarer. Especially for Broad Spectrum ATB which are recommended in case of invasive infection in ICU patients due to MDR pathogens such as Acinetobacter baumanii, extended spectrum ß-Lactamase producing (ESBL) pathogens or Multiresistant Staphylococcus aureus.
Furthermore, measuring ATB concentrations within the CSF at certain time-points is necessary but not sufficient to predict antimicrobial efficacy. First PK modelling is required to describe the full CSF concentrations versus time profiles. Then targets must be obtained from literature or determined for the relevant PD index, which may be, depending of the antibiotic, Time over Minimal Inhibitrice Concentration (T\>MIC), Area Under the Curve over MIC (AUC/MIC) or peak concentration over MIC (Cmax/MIC). Eventually Monte-Carlo simulations can be conducted to predict the probability of target attainment according to various dosing regimens to find the optimal one.
The goal of this multicenter population PK-PD study is to characterize CSF distribution and challenge recommended dosing regimens of 8 ATB indicated in CNS infections (vancomycin, daptomycin, ceftazidime, meropenem, colistin, linezolid, piperacillin-tazobactam and ceftaroline) and to study the Cefepime diffusion in the CSF, known to be highly neurotoxic.
Conditions
Interventions
- OTHER
-
Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use
Blood and cerebrospinal fluid pharmacocinetic samples at different time point
Sponsors & Collaborators
-
Poitiers University Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-06
- Primary Completion
- 2023-07-06
- Completion
- 2023-07-06
Countries
- France
Study Locations
More Related Trials
-
Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
NCT03681431 ·Status: COMPLETED ·Phase: PHASE2
-
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
NCT06738771 ·Status: RECRUITING
-
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance
NCT04771884 ·Status: RECRUITING
-
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
NCT04132115 ·Status: UNKNOWN
-
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
NCT02142075 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
NCT03032380 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy
NCT00214331 ·Status: COMPLETED
-
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT05094154 ·Status: COMPLETED ·Phase: PHASE4
-
PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship
NCT05486130 ·Status: UNKNOWN
-
Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use
NCT03489330 ·Status: COMPLETED
-
Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients
NCT02596984 ·Status: COMPLETED ·Phase: NA
-
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
NCT00752882 ·Status: UNKNOWN ·Phase: PHASE2
-
Staphylococcus Aureus Network Adaptive Platform Trial
NCT05137119 ·Status: RECRUITING ·Phase: PHASE4
-
Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device
NCT03317093 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit
NCT05696093 ·Status: RECRUITING ·Phase: PHASE3
-
Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration
NCT01171547 ·Status: UNKNOWN ·Phase: PHASE2
-
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
NCT04785924 ·Status: WITHDRAWN ·Phase: PHASE4
-
Population Pharmacokinetics of Anti-infectives in Hospitalized Patients
NCT02998411 ·Status: RECRUITING
-
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
NCT02583373 ·Status: COMPLETED ·Phase: PHASE1
-
Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis
NCT03967210 ·Status: COMPLETED
-
Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
NCT07247942 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
NCT00925093 ·Status: WITHDRAWN ·Phase: PHASE1
-
Pharmacokinetics of Antibiotics in Critically Ill Patients Receiving CVVHF
NCT04800952 ·Status: UNKNOWN ·Phase: NA
-
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
NCT02993575 ·Status: COMPLETED
-
Pharmacokinetic Study of Vancomycin, Clindamycin And/or Gentamicin Administration During Surgery Using a Microdialysis Procedure
NCT03845790 ·Status: COMPLETED ·Phase: PHASE1